GSK PLC 

GSK PLC (LSE: GSK) is a British multinational pharmaceutical and biotechnology company listed on the FTSE 100, with its global headquarters located in London.

Q3 FY24 Financial Results (Released on 30 October 2024)

1. Robust Growth in Specialty Medicines: GSK's Specialty Medicines segment experienced impressive sales growth of 19% YoY in Q3 FY24, driven by strong performances in oncology (+94%) and HIV (+12%). This growth highlights the success of new product launches and positions GSK well in a competitive market.

2. Resilient Core Earnings Amid Challenges: Despite a significant charge related to the Zantac settlement impacting total operating profit and EPS, GSK's core operating profit and EPS grew by 5% YoY for Q3 FY24. This resilience reflects effective cost management and the solid performance of Specialty Medicines, demonstrating GSK's ability to navigate financial challenges.

3. Positive R&D Progress and Pipeline Strength: GSK made substantial advancements in R&D across key therapeutic areas, with 11 positive Phase III trial results reported this year. Key approvals and designations, including new treatments in infectious diseases, oncology, and respiratory/immunology, signal a promising future pipeline and growth potential.

4. 2024 Guidance and Strong Dividend Commitment: GSK confirmed its full-year 2024 guidance, expecting turnover growth of 7% to 9% and core operating profit growth of 11% to 13%. Additionally, the declaration of a 15 pence dividend for Q3 and an anticipated full-year dividend of 60 pence per share underscores GSK’s commitment to returning value to shareholders amidst a solid business performance.

Share Price Chart

 Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

GSK PLC (LSE: GSK) was trading at the current market price of GBX 1,403.00 (as of 30 October 2024, 09:10 AM GMT+1)

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 30 October 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.

Note 4: Dividend Yield may vary as per the stock price movement.